Track lifetime anthracycline exposure against the 550 mg/m2 doxorubicin ceiling, or 450 mg/m2 when mediastinal radiotherapy has been given. The risk of congestive heart failure climbs steeply once the threshold is crossed.
Cumulative anthracycline dose is the strongest predictor of anthracycline-related cardiomyopathy. The thresholds shown are commonly cited guidance from Swain et al. (Cancer 2003) and product labelling: doxorubicin 550 mg/m² (400 mg/m² with prior chest radiotherapy or concurrent cardiotoxic agents), epirubicin 900 mg/m², daunorubicin 550 mg/m², idarubicin 150 mg/m², and mitoxantrone 140 mg/m².
These are guidance, not individualized limits. Baseline and serial LVEF assessment, patient age, prior mediastinal radiotherapy, and concurrent cardiotoxic agents all modify risk. Do not use this estimate as the sole basis for stopping or continuing therapy.
Enter the values for the scenario you are assessing. Track lifetime anthracycline exposure against the 550 mg/m2 doxorubicin ceiling, or 450 mg/m2 when mediastinal radiotherapy has been given. The risk of congestive heart failure climbs steeply once the threshold is crossed. Use the doxorubicin lifetime limit result to inform your calculation.